Lactobacillus KCTC 0774BP and acetobacter KCTC 0773BP for treatment or prevention of obesity and diabetes mellitus

• US 6,808,703 B2
• Filed: 05/16/2001
• Issued: 10/26/2004
• Est. Priority Date: 05/17/2000
• Status: Expired due to Term

• Current Assignee: Bioneer Corporation
• Original Assignee: Bioneer Corporation
• Inventors: Park, Han Oh, Kim, Bong Cheol, Joung, Hea Jung, Kim, Hang Rae, Bang, Young Bae
• Primary Examiner(s): Naff, David
• Assistant Examiner(s): Ware, Deborah K.
• Application Number:
  US09/855,836
• Publication Number:
  US 20020037577A1
• Time in Patent Office: 1,259 Days
• Field of Search: 424/93.4, 424/93.45, 424/93.46, 435/252.9, 435/823, 435/853-856, 435/243, 435/252.1, 435/252.5, 435/261
• US Class Current: 424/93.4
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12R 2001/02 Acetobacter
• CPC Class Codes: C12R 2001/225 Lactobacillus
• CPC Class Codes: Y10S 435/823 Acetobacter
• CPC Class Codes: Y10S 435/853 Lactobacillus

Abstract

The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms. Preferred microorganisms are Lactobacillus sp. BC-Y009 and Acetobacter sp. BC-Y058.

Claims

1. A biologically pure strain of Lactobacillus sp. BC-Y009 (KCTC-774BP).

2. A biologically pure strain of Acetobacter sp. BC-Y058 (KCTC-773BP).

3. A pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus in an amount effective to treat obesity and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition according to claim 3, which is a formulation suitable for oral administration.

5. The pharmaceutical composition according to claim 3, which is a formulation coated with enteric coating materials.

6. The pharmaceutical composition according to claim 4, which is a formulation coated with enteric coating materials.

7. A pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus C-Y009 in an amount effective to treat diabetes mellitus and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition according to claim 7, which is a formulation suitable for oral administration.

9. The pharmaceutical composition according to claim 7, which is a formulation coated with enteric coating materials.

10. A method for treating obesity, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009 in an amount effective to treat obesity and a pharmaceutically acceptable carrier.

11. The method according to claim 10, wherein the pharmaceutical composition is a formulation suitable for oral administration.

12. The method according to claim 11, wherein the pharmaceutical composition is a formulation coated with enteric coating materials.

13. The method according to claim 10, wherein the pharmaceutical composition is a formulation coated with enteric coating material.

14. A method for treating diabetes mellitus, corn rising administering to a subject in need thereof a pharmaceutical composition comprising at east one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009 in an amount effective to treat diabetes mellitus and a pharmaceutically acceptable carrier.

15. The method according to claim 14, wherein the pharmaceutical composition is a formulation suitable for oral administration.

16. The method according to claim 14, wherein the pharmaceutical composition is a formulation coated with enteric coating materials.

17. A method for controlling weight gain, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009 in an effective amount and a pharmaceutically acceptable carrier.

18. The method according to claim 17, wherein the pharmaceutical composition is suitable for oral administration.

19. The method according to claim 17, wherein the pharmaceutical composition is coated with enteric coating materials.

20. A method for controlling blood glucose level, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009 in an effective amount and a pharmaceutically acceptable carrier.

21. The method according to claim 20, wherein the pharmaceutical composition is suitable for oral administration.

22. The method according to claim 20, wherein the pharmaceutical composition is coated with enteric coating materials.

23. The method according to claim 20, wherein a normal blood glucose level is not affected.

24. A method for controlling absorption of blood lipid, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter C-Y058 and Lactobacillus BC-Y009 in an effective amount and a pharmaceutically acceptable carrier.

25. The method according to claim 24, wherein the pharmaceutical composition is suitable for oral administration.

26. The method according to claim 24, wherein the pharmaceutical composition is coated with enteric coating materials.